Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug:30 Suppl 4:iv86-95.
doi: 10.1093/ndt/gfv252.

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes

Michelle J Pena  1 , Dick de Zeeuw  1 , Harald Mischak  2 , Joachim Jankowski  3 , Rainer Oberbauer  4 , Wolfgang Woloszczuk  5 , Jacqueline Benner  5 , Guido Dallmann  6 , Bernd Mayer  7 , Gert Mayer  8 , Peter Rossing  9 , Hiddo J Lambers Heerspink  1
Affiliations
Review

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes

Michelle J Pena et al. Nephrol Dial Transplant. 2015 Aug.

Abstract

Diabetic kidney disease occurs in ∼ 25-40% of patients with type 2 diabetes. Given the high risk of progressive renal function loss and end-stage renal disease, early identification of patients with a renal risk is important. Novel biomarkers may aid in improving renal risk stratification. In this review, we first focus on the classical panel of albuminuria and estimated glomerular filtration rate as the primary clinical predictors of renal disease and then move our attention to novel biomarkers, primarily concentrating on assay-based multiple/panel biomarkers, proteomics biomarkers and metabolomics biomarkers. We focus on multiple biomarker panels since the molecular processes of renal disease progression in type 2 diabetes are heterogeneous, rendering it unlikely that a single biomarker significantly adds to clinical risk prediction. A limited number of prospective studies of multiple biomarkers address the predictive performance of novel biomarker panels in addition to the classical panel in type 2 diabetes. However, the prospective studies conducted so far have small sample sizes, are insufficiently powered and lack external validation. Adequately sized validation studies of multiple biomarker panels are thus required. There is also a paucity of studies that assess the effect of treatments on novel biomarker panels and determine whether initial treatment-induced changes in novel biomarkers predict changes in long-term renal outcomes. Such studies can not only improve our healthcare but also our understanding of the mechanisms of actions of existing and novel drugs and may yield biomarkers that can be used to monitor drug response. We conclude that this will be an area to focus research on in the future.

Keywords: CKD; biomarker panels; metabolomics; novel biomarkers; proteomics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

  NODES
INTERN 4
twitter 2